1 citations
,
October 2023 in “BMC oral health” Two patients treated with TAC for mouth fibrosis improved but developed Cushing's Syndrome symptoms.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
56 citations
,
March 2010 in “Journal of Dermatology” Most cases of Temporal Triangular Alopecia are found in early childhood and may be related to genetic conditions.
3 citations
,
May 2018 in “Psychiatry and Clinical Psychopharmacology” N-acetylcysteine may help treat trichotillomania.
35 citations
,
September 2011 in “The Journal of Dermatology” Trichoscopy helps accurately diagnose temporal triangular alopecia.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
1 citations
,
September 2024 in “Indian Journal of Postgraduate Dermatology” Trichoscopy effectively diagnoses temporal triangular alopecia in children.
October 2025 in “Diagnostics” Temporal triangular alopecia is a harmless, non-progressive hair loss condition.
11 citations
,
March 2002 in “Pediatric Dermatology” Temporal triangular alopecia is a non-scarring hair loss seen in some Asian children.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
January 2023 in “Indian Dermatology Online Journal” A 23-year-old man has a benign, non-progressive hair loss patch that doesn't respond to treatment but can be cosmetically treated.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
September 2025 in “Stem Cell Research & Therapy” TAZ boosts fat cell formation in goat stem cells by activating a specific signaling pathway.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
Introducing the OTC gene improved symptoms in mice with OTC deficiency.
15 citations
,
February 2015 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Dermoscopy helps accurately diagnose temporal triangular alopecia, avoiding unnecessary treatments.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
11 citations
,
March 2024 in “Cell and Tissue Research” Telocytes have potential in therapy and tissue regeneration, but challenges in identification and cultivation remain.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.